Selected announcements | Tencent Music Q1 adjusted net profit of 1.81 billion yuan, up 23.9% year on year; Kingsley Biotech: its legendary biotech Q1 net loss narrowed year on year
China Life Insurance: The cumulative original premium income for the first 4 months was about 371.2 billion yuan, an increase of 3.9% over the previous year; China Resources Land: The cumulative contract sales amount for the first 4 months was approximately RMB 72.0 billion.
Pharmaceutical Biotech (02269) spent HK$31.967 million to buy back 2.261,000 shares on May 13
Pharmaceutical Biotech (02269) issued an announcement to spend HK$31.967 million on May 13, 2024 to repurchase 2...
Zhitong Hong Kong Stock Connect Active Trading | May 13
On May 13, 2024, Yao Ming Biotech (02269.HK), CNOOC (00883.HK), and Tencent Holdings (00700.HK) ranked in the top 3 of Shanghai-Hong Kong Stock Connect (southbound) turnover, with turnover values of RMB 2,052 billion, RMB 1,959 billion, and RMB 1,888 billion respectively; Yingfu Fund (02800.HK), Pharmaceutical Biotech (02269.HK), and Tencent Holdings (00700.HK) ranked in the top 3 trading volume of Shenzhen-Hong Kong Stock Connect (Southbound) $1,814 million and 13.26, respectively 100 million yuan, 13.16 billion
A quick look at the Hong Kong market | The three major indices have risen one after another. Technology Network stocks and power stocks are popular. Bilibili has risen more than 6%, and Huadian International has risen nearly 8%
Biotech stocks had mixed ups and downs. Pharmaceutical and Ming Union fell%, and Jinxin Fertility rose%; shipping stocks rose, with Dongfang Overseas International, COSCO Marine Control, and COSCO Marine Energy up nearly 6%.
Intraday quick overview | The Science Index rose more than 1% to reach the 4,000 mark; port transport stocks were strong, and COSCO Marine Control rose more than 6%
Water stocks soared across the board. China Water Services rose more than 9%, Beijing Water Group rose more than 8%; high-speed rail infrastructure stocks collectively rallied, CRRC rose more than 9%, and Times Electric rose nearly 7%.
“Pharmacovigilance”, open high and walk low
Glonghui, May 13 | Hong Kong stocks opened high and went low, and Pharmaceutical Kant erased gains. Previously, it had risen by more than 15%; Yao Ming Biotech fell more than 7%, and had previously risen by more than 6%.
Shares of Yao Ming Kang De and Pharmaceutical Biotech rose
Shares of Yao Ming Kang De and Pharmaceutical Biotech rose
Hong Kong stocks opened, the Hang Seng Index fell 0.31%, and the Science Index opened down 0.94%. Pharmaceutical stocks generally rose, Pharma Ming Kangde rose nearly 15%, and Pharmaceutical Biotech rose nearly 8%.
Hong Kong stocks opened, the Hang Seng Index fell 0.31%, and the Science Index opened down 0.94%. Pharmaceutical stocks generally rose, Pharma Ming Kangde rose nearly 15%, and Pharmaceutical Biotech rose nearly 8%.
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Hong Kong Stock Afternoon Review | The three major indices rose sharply, domestic housing stocks and biotech stocks strengthened, Shimao Group rose more than 42%, and Ziding Pharmaceutical rose nearly 17%
Science and network stocks generally rose; Meituan rose more than 4%, and Bilibili rose nearly 3%; shipping stocks generally rose, with COSCO Maritime Control rising by more than 6%, and Orient Overseas International rising more than 5%.
Changes in Hong Kong stocks | Pharmaceutical Biotech (02269) rose more than 5%, leading the CRO concept financing environment, which is expected to improve the market and continue to monitor the progress of the Aesthetic Biology Act
CRO concept stocks generally rose in early trading. As of press release, Pharmaceuticals (02269) rose 4.67% to HK$14.78; Kanglong Chemical (03759) rose 4.15% to HK$10.28; Pharmaceuticals (02359) rose 3.02% to HK$37.5; and Tiger Pharmaceuticals (03347) rose 2.58% to HK$35.8.
Big Bank Ratings | Jefferies: From the perspective of market accounts, Yao Ming Biotech is currently at an inflection point rating “buying”
Glonghui, May 9 | Jefferies released a report saying that from the perspective of market accounts, Yao Ming Biotech is currently at an inflection point, and it is believed that its risk and reward curves tend to rise more than decline. The bank gave it a “buy” rating, with a target price of HK$53. Jefferies pointed out that investors are reaching consensus on the geopolitical issues faced by Pharmacovigilance. As the US Biological Act progresses, in particular, how to handle existing contracts will become more clear. Jeffrey explained that investors currently assume that the bill will be passed in some form; the bill should not be as severe as it seems, and they estimate that new projects from Yao Ming Biotech and even its Chinese counterpart will be in the next 3 to
The Hong Kong stock CXO concept fluctuated and strengthened, and Pharmaceutical Biotech rose more than 5%
The CXO concept of Hong Kong stocks fluctuated and strengthened. Yao Ming Biotech rose more than 5%, Kanglong Chemical and Pharmaceutical Kangde rose more than 4%, and Kingsley Biotech and Zhaoyan Pharmaceutical followed suit.
The biomedical sector of Hong Kong stocks strengthened, and BaiGene rose more than 5%
Glonghui, May 9 | BeiGene's increase extended to more than 5%, Pharmaceutical Biotech and Rongchang Biotech rose nearly 3%, and Cansino Biotech rose more than 1%.
Research and Development | China Merchants Securities: Drastic reduction in the target price of Pharmaceutical Biotech to HK$13, downgrading the rating to “neutral”
Glonghui, May 8 | China Merchants Securities issued a report, arguing that the hawkish monetary policy of the Federal Reserve will slow down the recovery of drug development and manufacturing (CDMO) performance in the current fiscal year. It is expected that the possibility that Yao Ming Biotech's revenue will increase by medium to high units in this fiscal year will decrease, so its target price was drastically lowered from HK$45 to HK$13, and the rating was downgraded from “increase in holdings” to “neutral”. The bank lowered Yao Ming Biotech's revenue and adjusted net profit forecasts for the current fiscal year by 12% and 17%, respectively, to reflect a further slowdown in the company's overall revenue growth. According to China Merchants Securities, downgrading Yao Ming Biotech this time is counterproductive
May 7 Repurchase Collection | Kuaishou-W, Hang Seng Bank and others bought back one after another, of which Kuaishou-W cost HK$49.499 million
According to documents disclosed by the Hong Kong Stock Exchange on May 8, $Kuaishou-W (01024.HK) $, $Hang Seng Bank (00011.HK) $, etc. repurchased shares. ① $Kuaishou-W (01024.HK) $ repurchased 844,000 shares of the same share with different rights on May 7, involving an amount of HK$49.499 million. The repurchase price for each share ranged from HK$59.95 to HK$58.5. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 58.722,300 shares, accounting for 1.355% of the number of shares issued when the ordinary resolution was passed. ②
Pharmaceutical Biotech (02269) spent HK$198292 million to buy back 1.37 million shares on May 7
Pharmaceutical Biotech (02269) announced that on May 7, 2024, the company spent HK$198292 million...
A quick look at the Hong Kong market | The three major indices have collectively pulled back, and the science index fell more than 2% to 4,000 points; domestic housing stocks rose against the market, and Xincheng Development rose nearly 6%
Technology Network stocks generally fell; Bilibili fell more than 6%, Kuaishou fell nearly 5%, and Meituan fell nearly 4%; copper concept stocks strengthened, Wanguo International Mining rose nearly 10%, and China's nonferrous mining industry rose more than 4%.
Hong Kong Stock Afternoon Review | The three major indices of Hong Kong stocks pulled back, and the Tech Index fell nearly 2%; PV stocks reversed the market, and GCL Technology rose more than 6%
Technology Network stocks declined; Bilibili fell more than 6%, NetEase fell more than 4%, Kuaishou and Meituan fell nearly 4%; as concept stocks declined, Huazhu Group fell more than 3%, and Jiumaojiu fell nearly 3%.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
No Data